{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:40:16Z","timestamp":1758937216591,"version":"3.44.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.leukres.2022.106903","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T21:31:31Z","timestamp":1655328691000},"page":"106903","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database"],"prefix":"10.1016","volume":"119","author":[{"given":"Noa","family":"Rippel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Zubizarreta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolai","family":"Podoltsev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Heaney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Kuykendall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Casey","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamile M.","family":"Shammo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Fleischman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Kremyanskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulraheem","family":"Yacoub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.leukres.2022.106903_bib1","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.leukres.2022.106903_bib2","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood-2018-99-111946","volume":"132","author":"Mascarenhas","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2022.106903_bib3","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1182\/blood.2018893545","article-title":"Oral idasanutlin in patients with polycythemia vera","volume":"134","author":"Mascarenhas","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2022.106903_bib4","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/asheducation-2017.1.480","article-title":"What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?","volume":"2017","author":"Vannucchi","year":"2017","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"issue":"10","key":"10.1016\/j.leukres.2022.106903_bib5","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.6004\/jnccn.2017.0157","article-title":"NCCN guidelines insights: myeloproliferative neoplasms, version 2.2018","volume":"15","author":"Mesa","year":"2017","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"5","key":"10.1016\/j.leukres.2022.106903_bib6","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1055\/s-2007-996124","article-title":"European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): a randomized trial","volume":"23","author":"Landolfi","year":"1997","journal-title":"Semin. Thromb. Hemost."},{"issue":"2","key":"10.1016\/j.leukres.2022.106903_bib7","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.leukres.2022.106903_bib8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.leukres.2022.106903_bib9","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.leukres.2022.106903_bib10","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1007\/s00277-014-2152-7","article-title":"Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea","volume":"93","author":"Alvarez-Larran","year":"2014","journal-title":"Ann. Hematol."},{"issue":"2","key":"10.1016\/j.leukres.2022.106903_bib11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s11899-020-00564-7","article-title":"Novel therapies in polycythemia vera","volume":"15","author":"Tremblay","year":"2020","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"5","key":"10.1016\/j.leukres.2022.106903_bib12","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.leukres.2022.106903_bib13","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3324\/haematol.2016.143644","article-title":"Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial","volume":"101","author":"Verstovsek","year":"2016","journal-title":"Haematologica"},{"issue":"20","key":"10.1016\/j.leukres.2022.106903_bib14","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","article-title":"Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference","volume":"113","author":"Barosi","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2022.106903_bib15","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","article-title":"Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera","volume":"119","author":"Alvarez-Larran","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2022.106903_bib16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2141.2006.06430.x","article-title":"The haematocrit and platelet target in polycythemia vera","volume":"136","author":"Di Nisio","year":"2007","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.leukres.2022.106903_bib17","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2022.106903_bib18","first-page":"138","article-title":"A real-world evaluation of the association between elevated blood counts and thrombotic events in polycythemia vera (analysis of data from the REVEAL study)","author":"Gerds","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2022.106903_bib19","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1111\/j.1538-7836.2010.03970.x","article-title":"Anagrelide represses GATA-1 and FOG-1 expression without interfering with thrombopoietin receptor signal transduction","volume":"8","author":"Ahluwalia","year":"2010","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.leukres.2022.106903_bib20","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.leukres.2004.10.002","article-title":"Anagrelide Study G. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders","volume":"29","author":"Fruchtman","year":"2005","journal-title":"Leuk. Res."},{"issue":"3","key":"10.1016\/j.leukres.2022.106903_bib21","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/ejh.13454","article-title":"Anagrelide in Essential Thrombocythemia (ET): results from 150 patients over 25 years by the \u201cPh1-negative Myeloproliferative Neoplasms Latium Group\u201d","volume":"105","author":"Mazzucconi","year":"2020","journal-title":"Eur. J. Haematol."},{"issue":"1","key":"10.1016\/j.leukres.2022.106903_bib22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3324\/haematol.2017.174672","article-title":"Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study","volume":"103","author":"Birgegard","year":"2018","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.leukres.2022.106903_bib23","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V97.4.863","article-title":"Long-term use of anagrelide in young patients with essential thrombocythemia","volume":"97","author":"Storen","year":"2001","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2022.106903_bib24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.leukres.2022.106903_bib25","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106903_bib26","doi-asserted-by":"crossref","unstructured":"L. Ronner, N. Podoltsev, J. Gotlib, M.L. Heaney, A.T. Kuykendall, C. O'Connell, et al., Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis. Blood 135 (19) (2020) 1696\u2013703.","DOI":"10.1182\/blood.2019003347"},{"issue":"20","key":"10.1016\/j.leukres.2022.106903_bib27","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106903_bib28","series-title":"Wisconsin Clinical Cancer Center. Biostatistics. A Confidence Interval for Median Survival Time","first-page":"21","author":"Brookmeyer","year":"1978"},{"issue":"10","key":"10.1016\/j.leukres.2022.106903_bib29","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/cncr.20646","article-title":"Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile","volume":"101","author":"Steurer","year":"2004","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.leukres.2022.106903_bib30","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1159\/000509376","article-title":"Cardiovascular risk in polycythemia vera: thrombotic risk and survival: can cytoreductive therapy be useful in patients with low-risk polycythemia vera with cardiovascular risk factors?","volume":"43","author":"Mancuso","year":"2020","journal-title":"Oncol. Res Treat."},{"issue":"3","key":"10.1016\/j.leukres.2022.106903_bib31","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s12012-020-09615-0","article-title":"Cardiovascular safety of anagrelide hydrochloride versus hydroxyurea in essential thrombocythaemia","volume":"21","author":"Gotic","year":"2021","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.leukres.2022.106903_bib32","first-page":"138","article-title":"European Leukemianet (ELN) response predicts disease progression but not thrombosis or death in polycythemia vera (PV): an analysis of a multicenter database","author":"Tremblay","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2022.106903_bib33","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood.V80.8.1965.1965","article-title":"Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo","volume":"80","author":"Landolfi","year":"1992","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622001291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622001291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:02:31Z","timestamp":1758934951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212622001291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":33,"alternative-id":["S0145212622001291"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106903","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106903","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106903"}}